Adicet Prula-cel: 54% DORIS Remission in Lupus Phase 1

Adicet Bio (Nasdaq: ACET) reported Phase 1 data showing that its off-the-shelf CD20 CAR-T, prula-cel, drove 54% of evaluable lupus patients into DORIS remission at the 12-month mark. The results were presented Monday on a dataset of 22 efficacy-evaluable patients, with a safety readout across 24 patients as of an August 28 data cutoff.

DORIS (Definition of Remission in Systemic Lupus) is the field’s standard for declaring a lupus patient in remission. Hitting it in 54% of patients, with half of the lupus nephritis subgroup achieving a complete renal response, marks the first meaningful durability print for an allogeneic, off-the-shelf cell therapy in lupus. Every patient had failed at least three prior therapies, and 71% had failed four or more.

Mechanism and Why the Cell Design Matters

The differentiator is the cell design. Prula-cel is a gamma-delta allogeneic CAR-T targeting CD20 rather than CD19, meaning it depletes plasmablasts that CD19-only therapies can leave behind. CD20 sits on a broader swath of B-lineage cells, including some antibody-producing compartments that CD19-directed agents can miss, and in a disease where pathogenic autoantibodies are the problem, coverage breadth is the argument. The gamma-delta T-cell backbone matters too: unlike conventional alpha-beta CAR-T cells, gamma-delta T cells are less prone to graft-versus-host disease and less dependent on HLA matching, which is what makes an allogeneic, off-the-shelf product even plausible.

Because it is allogeneic, it skips the leukapheresis and multi-week manufacturing wait that have slowed autologous lupus CAR-T programs from Kyverna and Cabaletta. Patients received a single outpatient dose. That logistics point is not cosmetic: autologous cell therapy capacity is finite, hospital slots are booked out, and a product that ships from the shelf could serve far more of the lupus population than vein-to-vein manufacturing allows.

The durability picture matters most. Responders stayed in remission through 12 to 21 months of follow-up, with all patients coming off immunosuppressants and all but one cutting background steroids to 5 mg or less of prednisone daily. Adicet’s 8-K frames a roughly 40% complete renal response as the clinically meaningful bar for cell therapy in lupus nephritis; 50% clears it.

Safety held up. There was no cytokine release syndrome above Grade 2, no ICANS, and no immune effector cell hemophagocytic syndrome. Grade 1 or 2 cytokine release syndrome occurred in 25% of patients, and Grade 3 or higher infections in 8.3%. All 22 efficacy-evaluable patients saw CD19+ B cells become undetectable, followed by naïve-dominant B-cell reconstitution, and 91% of anti-dsDNA-positive patients posted antibody reductions.

What It Means for the Trade

Shares closed at $9.02, and this is a roughly $88 million micro-cap, so the trade is a binary on institutional attention rather than fundamentals. The first meaningful durability print for an allogeneic cell therapy in lupus puts ACET on a short list of names to watch in the autoimmune CAR-T theme, which has otherwise been dominated by far larger players. The next catalyst is the registrational-study plan: the company said it plans to advance toward a registrational study by the end of 2026 and to discuss expanding it beyond lupus nephritis, given the DORIS rate observed. A protocol design, an FDA alignment announcement, or word that the study expands into additional indications would each be incremental proof points.

The competitive context matters for the timeline. Autologous CAR-T programs in lupus have already produced impressive remission data; prula-cel’s edge is not that remission is possible but that it may be achievable without the manufacturing bottleneck. If allogeneic products work, the entire cost and capacity curve of autoimmune cell therapy bends. That thesis is why this dataset got attention despite the small sample.

Risks and What Could Go Wrong

The honest caveat is sample size. Twenty-two efficacy-evaluable patients is small, and the field’s open question, whether remission holds after B-cell repopulation, is only now getting its first 12-to-21-month look. There is no approval path yet. A single-arm Phase 1 in a heterogeneous disease like lupus can look very different when a randomized, larger trial runs — patient selection and baseline severity move DORIS rates materially.

Allogeneic-specific risks also apply: persistence of the dosed cells can be shorter than with autologous products, and repeat dosing, rejection, or manufacturing lot-to-lot consistency are all questions a 24-patient study cannot answer. Infection risk (8.3% Grade 3 or higher) is real in a population that then sits B-cell-depleted. And the financing path for a micro-cap running cell-therapy trials is a standing overhang; advancing to a registrational study costs real money.

For context on how prula-cel fits the broader autoimmune CAR-T picture, see the ACET prula-cel primer. The full readout is on Adicet’s investor site.